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Abstract: PURPOSE: Urinary tract infections (UTI) are one of the most common reasons for prescrib-
ing antibiotics in primary care. In Switzerland, the Swiss Center for Antibiotic Resistances (ANRESIS)
provides resistance data by passive surveillance, which overestimates the true resistance rates. The aim
of this study was to provide actual data of the antimicrobial resistance patterns in patients with UTI in
Swiss primary care. METHODS: From June 2017 to August 2018, we conducted a cross-sectional study
in 163 practices in Switzerland. We determined the resistance patterns of uropathogens in patients with
a diagnosis of a lower UTI and analyzed risk factors for resistance. Patients with age < 18 years, preg-
nancy or a pyelonephritis were excluded. RESULTS: 1352 patients (mean age 53.8, 94.9% female) were
included in the study. 1210 cases (89.5%) were classified as uncomplicated UTI. Escherichia coli (E. coli)
was the most frequent pathogen (74.6%). Susceptibility proportions of E. coli to ciprofloxacin (88.9%)
and trimethoprim-sulfamethoxazol (TMP/SMX) (85.7%) were significantly higher than the proportions
reported by ANRESIS. We found high susceptibility to the recommended first-line antibiotics nitrofuran-
toin (99.5%) and fosfomycin (99.4%). Increasing age, antimicrobial exposure and a recent travel history
were independently associated with resistance. DISCUSSION: In this study, we report actual data on the
resistance patterns of uropathogens in primary care in Switzerland. Escherichia coli showed low resistance
rates to the recommended first-line antibiotics. Resistance to TMP/SMX was significantly lower than
reported by ANRESIS, making TMP/SMX a suitable and cheap alternative for the empirical treatment.
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34 Abstract: 
 
35 Purpose: Urinary tract infections (UTI) are one of the most common reasons for prescribing antibiotics in primary 
 
36 care. In Switzerland, the Swiss Center for Antibiotic Resistances (ANRESIS) provides resistance data by passive 
 
37 surveillance, which overestimates the true resistance rates. The aim of this study was to provide actual data of the 
 
38 antimicrobial resistance patterns in patients with UTI in Swiss primary care. 
 
39 Methods: From June 2017 to August 2018, we conducted a cross-sectional study in 163 practices in Switzerland. 
 
40 We determined the resistance patterns of uropathogens in patients with a diagnosis of a lower UTI and analysed 
 
41 risk factors for resistance. Patients with age <18 years, pregnancy or a pyelonephritis were excluded. 
 
42 Results: 1,352 patients (mean age 53.8, 94.9% female) were included in the study. 1,210 cases (89.5%) were 
 
43 classified as uncomplicated UTI. E. coli was the most frequent pathogen (74.6%). Susceptibility proportions of E. 
 
44 coli to ciprofloxacin (88.9%) and trimethoprim-sulfamethoxazol (TMP/SMX) (85.7%) were significantly higher 
 
45 than the proportions reported by ANRESIS. We found high susceptibility to the recommended first line antibiotics 
 
46 nitrofurantoin (99.5%) and fosfomycin (99.4%). Increasing age, antimicrobial exposure and a recent travel history 
 
47 were independently associated with resistance. 
 
48 Discussion: In this study, we report actual data on the resistance patterns of uropathogens in primary care in 
 
49 Switzerland. E. coli showed low resistance rates to the recommended first line antibiotics. Resistance to TMP/SMX 
 
50 was significantly lower than reported by ANRESIS, making TMP/SMX a suitable and cheap alternative for the 
 





54 Urinary tract infections (UTI) are one of the most common infections worldwide [1] and almost every second 
 
55 women will have at least one episode during lifetime [2]. Although UTIs may be self-limiting, UTIs are one of the 
 
56 most common reasons for prescribing antibiotics in primary care [3]. A progress to an upper UTI / pyelonephritis 
 
57 is rare [4], but seem to be more common without antibiotic therapy. Furthermore, antibiotic therapy results in a 
 
58 faster  symptom  relief  compared  to  placebo  or  anti-inflammatory  therapies  [5,  6].   Most  guidelines  do not 
 
59 recommend a microbiological diagnosis in cases of an uncomplicated UTI (uUTI) before treatment [7, 8]. The 
 
60 choice of the empirical antibiotic treatment depends on the expected bacteria and their antibiotic resistance 
 
61 patterns. To date fosfomycin, nitrofurantoin, pivmecillinam and trimethoprim-sulfamethoxazol (TMP/SMX) were 
 
62 recommended as empirical first line therapy in most guidelines. The use of TMP/SMX is limited to areas, where 
 
63 local resistance rates are known and where they do not exceed 20% [7]. In Switzerland,  the Swiss Center for 
 
64 Antibiotic Resistances (www.anresis.ch) provides a nationwide passive surveillance [9]. However, because in 
 
65 cases of an uUTI no microbiological diagnostic is done in most cases, passive surveillance may overestimate the 
 
66 resistance prevalence in the community setting [10]. The aim of this study was to provide actual data of the 
 





70 This cross-sectional study was conducted from June 2017 to August 2018 in 161 Swiss primary care practices as 
 
71 well as in two large “walk-in” practices. The general practitioners (GP) proposed study participation to all patients 
 
72 aged 18 and older with a clinical diagnosis of a lower UTI in consecutive order. Pregnant women and patients with 
 
73 a pyelonephritis were excluded. No patient could be included twice in the study in case of recurrence or treatment 
 
74 failure. Diagnostic criteria of an UTI (complicated and uncomplicated) were provided to all GPs to ensure 
 
75 diagnostic standardization [8]. UTI was defined as the new onset of typical symptoms (dysuria, pollakiuria, 
 
76 urgency or haematuria) and a positive urine dipstick (positive leucocytes). Uncomplicated cystitis was defined as 
 
77 cystitis in otherwise healthy women without the history or the clinical suspicion of any functional or anatomical 
 
78 abnormalities of the urinary tract. UTIs in male patients or in female patients with concomitant (urological) 
 
79 disorders  (according  to  Swiss  national  guidelines  [8])  were  considered  as  complicated.  In  case  of  study 
 
80 participation  and  signed  informed  consent,  a  urine  specimen  was  collected  for  microbiological  analysis. 
 
81 Furthermore, epidemiological and clinical data were recorded. Finally, the GP had to determine the final diagnosis 
 
82 (uncomplicated or complicated cystitis), and whether they would have done a microbiological analysis apart of 
 
83 the study. 
 
84 Resistance data from ANRESIS (2018 resistance data) were acquired by using the following selection criteria: All 
 
85 urinary Escherichia coli (E. coli) isolates from adult (age >15) outpatients (private physicians, ambulatories or 
 
86 emergency departments), (assessed 17.06.2019) (www.anresis.ch). Comparisons of regional susceptibility patterns 
 




89 Microbiological analysis: 
 
90 Urine samples for culture were collected in a sterile container containing boric acid as a preservative. The urine 
 
91 was plated onto a chromogenic and blood agar medium and an inhibition test for detection of a possible antibiotic 
 
92 pretreatment was performed. After 24/48h incubation time, positive culture was defined as growth of 10^3 colony 
 
93 forming units or more. Bacteria were subjected to an identification procedure by mass spectrometry (MALDI TOF) 
 
94 and to an automated antimicrobial susceptibility testing (Vitek 2). Intermediate resistance was handled as resistant 
 
95 for resistance analysis. 
 
96 Ethics: 
97 The study was approved by the local ethics committee (BASEC Number: 2016-01918) and every patient signed a 
 






101 Summary statistics were reported as means (standard deviation, SD), and number (percentage, %) as appropriate. 
 
102 Patient characteristics and microbiological results were compared between cUTI and uUTI; Independent sample 
 
103 Student’s t test was used for continuous variables and chi-square or Fisher’s test, as appropriate, were used for 
 
104 categorical variables. Antibiotic susceptible rates of E. coli were compared to the rates provided by Swiss passive 
 
105 surveillance using the Chi squared test with simulated p-values, computed by a Monte Carlo test with 2000 
 
106 replicates. The 95% confidence interval (CI) for the susceptible proportions were reported, too. Resistance to 
 
107 Fluoroquinolones (FC) means resistance to at least one out of ciprofloxacin, levofloxacin, moxifloxacin, or 
 
108 norfloxacin. Univariable and multivariable logistic regression models were performed to identify the association 
 
109 between patient characteristics, together with type of UTI, and antibiotics resistance rate of E.coli. Only women 
 
110 infected with E. coli were considered in the regression analysis. The study’s exploratory nature required non- 
 
111 parsimonious multivariable regression models to identify variables for further exploration in future studies. These 
 
112 models were performed using automatic stepwise selection estimation with likelihood ratio testing (P-value ≤0.20) 
 
113 specified as the test of significance to include or exclude variables. For all other tests, P ≤ 0.05 was considered 
 
114 statistically significant. As sensitivity analysis, we estimated the intracluster correlation coefficient (ICC), using a 
 
115 mixed regression model with a random effect at GP level. All analyses were carried out using statistical package 
 









120 1,454 patients were screened for study participation. 33 patients refused to participate. In total 1,421 urine samples 
 
121 were collected (Figure 1). 69 patients were excluded due to missing leukocyturia (46), age<18 (10), absence of 
 
122 classical symptoms (9), pregnancy (2), or other reasons (2). Finally, 1,352 urine samples were included in the 
 
123 overall analysis. Basic demographic and clinical information are shown in Table 1. 1,210 cases (89.5%) were 
 
124 reported as uUTI and 129 as cUTI (9.5%). Thirteen cases (1%) resulted unclassified, hence these cases were 
 
125 excluded for comparison analysis, but still included in the overall analysis. 94.9% of the participants were female. 
 
126 The overall mean age was 53.75 (standard deviation: 20.8) years. 
127 
 
128 Microbiological analysis 
 
129 Urine cultures were positive in 87.1% (1,117 cases) (Table 2). In 143 cases (12.1%) two pathogens were detected 
 
130 and 140 cases (11.9%) were considered as contaminated due to growth of 3 or more pathogens and were excluded 
 
131 from further analysis. Gram-negative rods were present in 86.8%, enterococci in 6.9% and other gram-positive 
 
132 bacteria in 19.4 % of all cases. However, growth of only gram-negative rods, enterococci or other  gram-positive 
 
133 bacteria in a culture was detected in 72.7%, 3.2% and 8.6%, respectively. E. coli was the most common pathogen 
 
134 and was found in 74.6% of all cases. Comparing the causing uropathogens in the uUTI and cUTI, there were no 
 
135 significant differences. 
 
136 Resistance proportions 
 
137 Resistance proportions were reported for E. coli (additional resistance proportions for Klebsiella spp., 
 
138 Enterobacter spp. and Proteus spp. were provided in Supplemental Table 4). E. coli showed high susceptibility 
 
139 rates to the recommended first line antibiotics fosfomycin (99.35%, 95% confidence interval [CI]: 99.34%- 
 
140 99.37%), nitrofurantoin (99.48%, 95% CI: 99.47%-99.5%), and TMP/SMX (85.66%, 95% CI: 85.58%-85.74%). 
 
141 With exception of the Geneva area, resistance proportions to TMP/SMX were below 20% in all areas of 
 
142 Switzerland.  Although not  statistically significant,  we  observed  the  lowest  susceptibility proportions against 
 
143 TMP/SMX in the French-speaking western areas of Switzerland. 88.89% (95% CI: 88.82%-88.96%) of the isolates 
 
144 were susceptible to ciprofloxacin (Table 3) and 85.40% (95% CI: 85.32%-85.48%) of the isolates were susceptible 
 
145 to norfloxacin. In comparison to the data provided by ANRESIS (passive surveillance), we found significantly 
 
146 higher susceptibility proportions of E. coli to both TMP/SMX and ciprofloxacin (p <0.001 in both groups). There 
 
147 were no significant differences in the susceptibility to fosfomycin and nitrofurantoin (p=0.14, and p= 0.543, 
 
148 respectively) between active and passive surveillance. With the exception of nitrofurantoin (p=0.011), susceptible 
 
149 proportions to the antibiotics did not differ significantly between the different regions across Switzerland in our 
 
150 study.  Nitrofurantoin susceptibility was reduced  in the south region of Switzerland  (susceptibility rate 90.9%), 
 
151 compared to the other regions (susceptibility rates >97.3%). However, this finding could be biased due to the very 
 
152 limited specimen numbers in the south region (n=11). 
 
153 Comparing the susceptibility proportions of E. coli in uUTI and cUTI, we found no significant differences 
 
154 (Supplemental Table 1). Furthermore, there was no significant difference in the susceptibility proportion to 
 
155 TMP/SMX in patients in which the GP would have done a urine analysis apart from the study, compared to the 
156 patients without a urine analysis. In contrast, susceptibility to ciprofloxacin was significant lower in patients in 
 
157 which the GP would have done a urine analysis apart from the study (Supplemental Table 2). 
 
158 Risk factors for E. coli resistance 
 
159 Univariate and multivariate logistic regression analysis for identifying variables as risk factors for antibiotic 
 
160 resistance to the recommended first line antibiotics (TMP/SMX, nitrofurantoin, and fosfomycin) or to FC in 
 
161 women infected with E. coli are shown in Table 4. Additional analysis for each antibiotic in separate were provided 
 




164 Analysing risk factors for resistance to any recommended first line antimicrobial agent, antibiotic exposure for any 
 
165 reason within the last 3 months and a recent travel to Africa were associated with an increased risk of resistance, 
 
166 which is also true for resistance to TMP/SMX alone. Compared to antimicrobial exposure for any reason, 
 
167 antimicrobial exposure specific for an UTI was not associated with an increased resistance. Age, a recent hospital 
 
168 stay, and a travel history to Oceania were associated with increased risk of resistance to fosfomycin, whereas no 
 
169 risk factors could be identified for resistance to nitrofurantoin. Resistance to FC was associated with age, living in 
 




172 In this study, we determined the frequency and susceptibility proportions of uropathogens in urinary tract 
 
173 infections in primary care in Switzerland. We found high susceptibility proportions of E. coli to the recommended 
 
174 first line antibiotics and higher susceptibility proportions for TMP/SMX and ciprofloxacin as reported by the Swiss 
 
175 national passive surveillance. 
 
176 E. coli is the most frequent pathogen in both uncomplicated and complicated UTI [11] and accounts for up to 95% 
 
177 of urinary tract infections [7] as also seen in our study. Knowledge of local resistance patterns of E.coli is therefore 
 
178 crucial for the consideration of an adequate empirical treatment. In our cohort, clinical significant growth, after 
 
179 excluding contaminated samples, could be detected in 76%, which is similar to other studies [12, 10]. E.coli was 
 
180 the most frequent pathogen and showed high susceptibility proportions to the recommended first line  antibiotics 
 
181 fosfomycin, nitrofurantoin, and TMP/SMX. Current guidelines recommend the use of TMP/SMX only if local 
 
182 susceptibility proportions exceed 80%. With exception of the Geneva area, this premise is fulfilled in all 
 
183 geographic areas of Switzerland. Although not statistically significant, we observed a trend for higher resistance 
 
184 proportions against TMP/SMX in the French-speaking western areas of Switzerland. This could be explained by 
185 the fact that the highest antibiotic prescription rates are also seen the French-speaking parts of Switzerland [13, 
 
186 14] and an association between resistance rates and antibiotic prescription is frequently reported in the  literature 
 
187 [15, 14]. 
 
188 Compared to the Swiss national passive surveillance, susceptibility proportions to TMP/SMX and ciprofloxacin 
 
189 were significantly higher in our cohort. This reflects the selection bias in passive surveillance systems, as 
 
190 microbiological analysis is not recommended in most outpatients with a uUTI and higher resistance rates are seen 
 
191 in patients with a cUTI [16]. Susceptibility proportions of nitrofurantoin and fosfomycin did not differ significantly 
 
192 from the reported proportions by ANRESIS. This is due to overall high susceptibility proportions (>98%) in both 
 
193 our cohort and ANRESIS. 
 
194 10 years ago, a similar study investigated the resistance proportions in around 1,000 outpatient UTI cases in the 
 
195 canton of Berne in Switzerland [10]. The reported susceptibility proportions of E. coli to TMP/SMX (71% to 80%) 
 
196 were lower than the susceptibility proportions in our study. The same is true for nitrofurantoin, with higher 
 
197 susceptibility proportions in our study. Resistance proportions to fosfomycin were similar in both studies. It seems 
 
198 that at least in the outpatient setting there is no deterioration of resistance patterns against fist line antimicrobial 
 
199 agents within the last decade, which is remarkable as the frequency of resistant uropathogens is steadily increasing 
 
200 [17, 16]. One the other hand, susceptibility to norfloxacin (the only reported FC), was reported higher compared 
 
201 to our study. 
 
202 It is generally considered, that susceptibility rates of uropathogens in uUTI are higher compared to cUTI [7, 12, 
 
203 18-21] and that E.coli is the most common uropathogen in both conditions, despite the wider microbiological 
 
204 spectrum in cUTI [22]. As expected in our study E. coli was the most frequent pathogen in both uUTI and cUTI 
 
205 (74.8% and 72.3%, respectively), but susceptibility proportions did not differ significantly between both groups. 
 
206 These findings could be explained by two reasons: First, the numbers of cUTI were relative low (<10%). Second, 
 
207 in contrast to the well-known and accepted definition of uUTI, the definition for cUTI is more heterogeneous. 
 
208 There is evidence, that for example in young men a UTI can be uncomplicated [23]. The microbiological patterns 
 
209 of causing pathogens in the different aetiologies of cUTI are unknown. Our findings, that there can be similarities 
 
210 in the resistance patterns and in the causing pathogens in both groups, support the need for a more detailed 
 
211 stratification and treatment recommendations of cUTI [11, 23] (at least for ambulatory care). National guidelines 
 
212 recommend a microbiological culture and the use of antibiotics with a good prostate penetration in UTI in men 
 
213 [8]. Both TMP/SMX and FC have an excellent prostate penetration. Due to the similar resistance rates in uUTI 
 
214 and cUTI in our cohort, empirical therapy with TMP/SMX seems to be feasible also in men until resistance analysis 
215 is available. According to pharmacological data also fosfomycin has an good penetration into the prostate [24], 
 
216 but today fosfomycin is not routinely used in the treatment of an prostatitis [22]. In contrast, nitrofurantoin does 
 
217 not penetrate into prostatic tissue adequately [25]. 
 
218 Multivariable regression analysis revealed age, prior antibiotic exposure and a recent travel history as risk factors 
 
219 for antibiotic resistance. These findings are consistent with the known risk factors reported in the literature [26- 
 
220 29] and these factors need to be considered in the choice of the empiric treatment. 
 
221 Strengths/limitations: In this prospective trial, we sampled urine specimen across all regions in Switzerland and 
 
222 all specimen were analysed in one central laboratory. The overall numbers of patients, which refused to participate 
 
223 and the exclusions were low (Figure 1), indicating a low risk of selection bias, assuming the data are representative 
 
224 for primary care in Switzerland; nevertheless certain subgroup analysis have to be interpreted with caution due to 
 
225 small sample sizes (e.g. comparisons across regions, multivariable modelling) and limited data (reason for 
 
226 classification uUTI vs. cUTI). 
 
227 Implications for Swiss primary care 
 
228 Current national and international guidelines recommend fosfomycin or nitrofurantoin for the empirical treatment 
 
229 of uUTI. Depending on the local resistance rate, TMP/SMX is an additional first line antimicrobial agent. In our 
 
230 cohort, we could report resistance proportions below 20% to TMP/SMX in nearly all areas of Switzerland. Thus, 
 
231 TMP/SMX remains a suitable antibiotic for the empirical treatment of uUTI and even cUTI in primary care in 
 
232 Switzerland, especially as the treatment costs of the standard regime TMP/SMX are similar to that of 
 
233 nitrofurantoin, but three times cheaper compared to fosfomycin. However, in patients with a systemic antibiotic 
 
234 exposure within the last three months or a travel history to Africa, clinicians should prefer a therapy with 
 
235 nitrofurantoin or fosfomycin, Of note, a recent multicentric study showed superiority of nitrofurantoin over 
 
236 fosfomycin [30]. 
 
237 In our cohort E. coli isolates showed high susceptibility proportions to FC. FC are highly effective in the treatment 
 
238 of UTIs and were recommended for the empirical therapy for many years. Despite UTIs, FC are important in the 
 
239 treatment in extra- urogenital infections like intra-abdominal infections, soft tissue, and bone and joint infections. 
 
240 Due to excessive use, increasing resistance rates not only in uropathogens were observed [7]. Increasing FC 
 
241 resistance rates are a serious public health treat [16], in addition to the general potential side effects like ecological 
 
242 damage to gut flora or tendinopathies. Therefore, we support the recommendations of current guidelines to avoid 
 
243 FC use in the empirical therapy in UTI [7, 8] despite the low resistance proportions. 
244 
 
245 In conclusion, we could show low resistance patterns to the recommended first line antibiotics fosfomycin, 
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